Shares of Galena Biopharma, Inc. (NASDAQ:GALE) traded up 3.2% during mid-day trading on Friday . The company traded as high as $0.31 and last traded at $0.30. 505,046 shares traded hands during trading, a decline of 28% from the average session volume of 704,665 shares. The stock had previously closed at $0.31.
Separately, Maxim Group reissued a “hold” rating on shares of Galena Biopharma in a research report on Wednesday, August 9th.
Galena Biopharma (NASDAQ:GALE) last issued its quarterly earnings results on Monday, August 14th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). During the same quarter in the prior year, the business posted $0.05 earnings per share. equities analysts predict that Galena Biopharma, Inc. will post -0.59 earnings per share for the current year.
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. increased its position in shares of Galena Biopharma by 1.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,332,434 shares of the biotechnology company’s stock valued at $774,000 after purchasing an additional 13,302 shares during the period. Virtu KCG Holdings LLC grew its holdings in shares of Galena Biopharma by 677.4% in the 2nd quarter. Virtu KCG Holdings LLC now owns 224,050 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 195,230 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Galena Biopharma in the 1st quarter worth $976,000. Institutional investors own 20.53% of the company’s stock.
WARNING: This piece was first published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another domain, it was illegally stolen and republished in violation of United States and international copyright & trademark laws. The original version of this piece can be viewed at https://transcriptdaily.com/2017/11/05/galena-biopharma-inc-gale-trading-3-2-higher.html.
Galena Biopharma Company Profile
Galena Biopharma, Inc is a biopharmaceutical company. The Company focuses on developing and commercializing targeted oncology therapeutics that address unmet medical needs. The Company’s development portfolio ranges from mid- to late-stage clinical assets, including cancer immunotherapy program led by NeuVax (nelipepimut-S), GALE-301 and GALE-302.
Receive News & Ratings for Galena Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galena Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.